September 10th 2025
The FDA has assigned a Prescription Drug User Fee Act date of July 11, 2026, for relacorilant as a treatment for platinum-resistant ovarian cancer.
September 4th 2025
FDA Approves First-Line Pembrolizumab Plus Chemo With or Without Bevacizumab for Cervical Cancer
October 13th 2021The FDA has approved the use of pembrolizumab plus chemotherapy with or without bevacizumab in patients with persistent, recurrent, or metastatic cervical cancer who have PD-L1 expression identified via an FDA-approved test.
Cemiplimab Improves OS Versus Chemotherapy Across Histologic Subtypes in Recurrent Cervical Cancer
May 14th 2021Results presented at part of the European Society for Medical Oncology Virtual Plenary show positive results of a phase 3 trial comparing cemiplimab with chemotherapy for previously treated cervical cancer.
Ronnie Shapira-Frommer, MD, Discusses Multidisciplinary Care to Treat Gynecologic Malignancies
April 12th 2021CancerNetwork® spoke with Ronnie Shapira-Frommer, MD, during the Society of Gynecological Oncology 2021 Virtual Annual Meeting on Women’s Cancer about her thoughts on the effect of the conference content across multidisciplinary specialties.
Oral Apixaban May Be Safe Alternative to Subcutaneous Enoxaparin for Thromboprophylaxis
July 27th 2020Within this study, satisfaction was markedly higher in those treated with apixaban, and adherence rates appeared to be similar between both modalities in women undergoing surgery for gynecologic cancer.
Adavosertib Induces Tumor Shrinkage in 30% of Patients with Uterine Serous Carcinoma
April 29th 2020A recent clinical trial’s results found that a targeted drug known as adavosertib caused tumors in nearly 30% of patients examined with uterine serous carcinoma, a hard-to-treat form of uterine cancer.
Interventions on Cervical Cancer Screening Increase Participation in Immigrant Women
April 13th 2020This study found that raising the awareness of general practitioners and highlighting the importance of encouraging immigrant women to participate in cervical cancer screening is a feasible and effective strategy to increase participation in the program.